Surmodics (SRDX) Projected to Post Earnings on Thursday

Surmodics (NASDAQ:SRDX - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, January 30th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $33.37 million for the quarter.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Stock Performance

SRDX stock traded down $0.30 during midday trading on Thursday, reaching $35.48. 139,345 shares of the company's stock traded hands, compared to its average volume of 340,666. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.96. The firm has a market capitalization of $507.15 million, a PE ratio of -43.80 and a beta of 1.21. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a 50-day moving average price of $38.88 and a two-hundred day moving average price of $39.23.

Insider Activity

In other news, CFO Timothy J. Arens sold 7,009 shares of the company's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now owns 70,350 shares of the company's stock, valued at approximately $2,774,604. This represents a 9.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on SRDX shares. StockNews.com initiated coverage on shares of Surmodics in a research report on Sunday. They issued a "hold" rating for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Thursday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $50.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).